ABSTRACT
A 19-year-old woman was admitted to our hospital with a complaint of residual feeling, frequency and pain on urination. Laboratory analysis revealed an elevated eosinophilia count in peripheral blood and white blood cell count in urine. Lymphocyte stimulation test of Chinese herb named "Seijoh-bohhuh-toh" showed a positive reaction. Bladder symptoms were improved after ceasing this Chinese herb. From these points, we considered that the Chinese herb might have caused eosinophilic cystitis. We report this rare case with a review of the literature.
Subject(s)
Cystitis/chemically induced , Medicine, Chinese Traditional/adverse effects , Eosinophilia/chemically induced , Female , Humans , Young AdultABSTRACT
A 5-month-old-male was brought to our hospital in April 2004 with left scrotal swelling. His serum alpha-fetoprotein AFP and human chorionic gonadotropin-beta levels were 6,862.9 and < 0.1 ng/ml, respectively. Computed tomography (CT) revealed no metastasis. Left high ligation of testis was performed. Pathological examination demonstrated Yolk sac tumor. He is alive without evidence of recurrence for 53 months postoperatively.
Subject(s)
Endodermal Sinus Tumor/diagnosis , Testicular Neoplasms/diagnosis , Chorionic Gonadotropin, beta Subunit, Human/blood , Endodermal Sinus Tumor/therapy , Humans , Infant , Male , Testicular Neoplasms/therapy , alpha-Fetoproteins/analysisABSTRACT
Splenosis is autotransplantation of splenic tissue and usually follow traumatic or surgical rupture of the spleen. We report two cases of splenosis which presented as a local recurrence after radical nephrectomy for left renal cell carcinoma (RCC). The patients were a 65- and a 71-year-old male, who had been operated for RCC including splenectomy because of disrupture of the splenic capsule 8 and 9 years earlier respectively. In both cases, follow up computed tomographic scans showed small nodules under the left diaphragm. Although we initially suspected local recurrence, we considered the possibility of splenosis. Both patients underwent technetium-99m Sn colloid scans and were diagnosed with splenosis successfully. Therefore, we could avoid unnecessary surgical explorations.
Subject(s)
Carcinoma, Renal Cell/diagnosis , Kidney Neoplasms/diagnosis , Neoplasm Recurrence, Local/diagnosis , Nephrectomy , Splenosis/diagnosis , Aged , Carcinoma, Renal Cell/surgery , Diagnosis, Differential , Humans , Kidney Neoplasms/surgery , Male , Postoperative Complications , Radionuclide Imaging , Splenosis/diagnostic imagingABSTRACT
The objective of this study was to know the effects of pelvic lymph node dissection on the survival of the patients who received radical cystectomy without neoadjuvant chemotherapy or radiotherapy. Between 1984 and 2000, 104 patients underwent operation at our institution for tumors clinically diagnosed as locally invasive bladder cancer (T2-4NxM0). Survival rates and 8 prognostic factors (age, sex, size, multiplicity, type, pT, N, pv) were analyzed by uni- and multivariate analysis. The significant factors were size, type, pT, N, pv by univariate analysis. Of these 5 factors, N factor was the most significant by multivariate analysis. Patients (N-) who had more than 20 lymph nodes retrieved showed better survival than the others.
Subject(s)
Lymph Node Excision/mortality , Lymph Nodes/pathology , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/surgery , Aged , Aged, 80 and over , Cell Count , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Multivariate Analysis , Neoplasm Invasiveness , Pelvis , Prognosis , Survival Rate , Urinary Bladder Neoplasms/pathologyABSTRACT
Between January 1989 and March 2002, we treated 299 male bladder cancer patients and 416 prostatic cancer patients. Of these, 17 patients (5.7% of the male bladder cancer patients and 4.1% of the prostatic cancer patients) had double cancer consisting of prostatic cancer and bladder cancer. The mean age at diagnosis of the first and second cancer was 71.6 years and 75.5 years, respectively. Of the 8 patients with synchronous tumors, 3 patients had latent prostate cancer when they underwent total cystoprostatectomy. The mean interval between the first and second cancer was 45.3 months. The mean follow-up period was 84.7 months (ranged from 5 to 324 months) and two patients died of cancer (bladder: 1, prostate: 1). In the literature, the coincidence of bladder cancer and prostatic cancer is the highest in the urological field. In follow up of either of these cancer patients, it is important to be aware of not only progression of the first cancer but also generation of a second cancer.
Subject(s)
Carcinoma, Transitional Cell , Neoplasms, Multiple Primary , Prostatic Neoplasms , Urinary Bladder Neoplasms , Aged , Aged, 80 and over , Carcinoma, Transitional Cell/mortality , Carcinoma, Transitional Cell/therapy , Humans , Male , Middle Aged , Prognosis , Prostatic Neoplasms/mortality , Prostatic Neoplasms/therapy , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/therapyABSTRACT
OBJECTIVE: To know the survival and prognostic factors of the patients who received radical cystectomy with or without neoadjuvant cisplatin-based chemotherapy. METHODS: Between 1977 and 2001, 201 patients underwent radical cystectomy at Yokohama City University and Yokosuka Kyosai Hospital whose tumor were clinically diagnosed as locally invasive bladder cancer (T2-4NxM0). Survival rates and 9 prognostic factors (Age, Size, Multiplicity, Type, Grade, p-stage, n,neoadjuvant chemotherapy, adjuvant chemotherapy) were analysed by Kaplan-Meier methods and Cox-proportional hazard model. RESULTS: The independent prognostic factors of these patients were size, multiplicity, type, grade, p-stage, n, neoadjuvant by univariate analysis. Of these 7 factors, n, neoadjuvant, p-stage and size are significant by multivariate analysis. Survival of the patients who received neoadjuvant cisplatin-based chemotherapy followed cystectomy is better than cystectomy only group by Kaplan-Meier method. CONCLUSIONS: From these rusults, neoadjuvant cisplatin-based chemotherapy play some role for survival of the patients with invasive bladder cancer.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Transitional Cell/drug therapy , Cystectomy , Urinary Bladder Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma, Transitional Cell/mortality , Carcinoma, Transitional Cell/radiotherapy , Carcinoma, Transitional Cell/surgery , Chemotherapy, Adjuvant , Cisplatin/administration & dosage , Doxorubicin/administration & dosage , Drug Administration Schedule , Female , Humans , Male , Methotrexate/administration & dosage , Middle Aged , Multivariate Analysis , Neoadjuvant Therapy , Prognosis , Proportional Hazards Models , Retrospective Studies , Survival Rate , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/radiotherapy , Urinary Bladder Neoplasms/surgery , Vinblastine/administration & dosageABSTRACT
To examine the incidence of recurrence, progression and survival in patients with grade 3 superficial bladder cancer after transurethral resection (TUR) and adjuvant intravesical instillation of Bacillus Calmette-Guérin (BCG), we retrospectively studied 39 patients with grade 3 superficial bladder cancer. Nineteen patients with high-grade superficial bladder cancer (pTa, pT1) and 5 patients with grade 3 carcinoma in situ (CIS) received intravesical instillation of BCG after transurethral resection of the bladder tumor (BCG group and CIS-BCG group). The Tokyo 172 strain BCG was given for 8 weeks, as a rule, in a dose of 80 mg in 40 ml of saline instilled into the bladder. As a control, 15 patients with grade 3 superficial bladder cancer who did not receive BCG therapy after TUR were compared (non-BCG group). Of the BCG group (n=19), 4 patients (21.1%) had recurrent tumor and 3 had invasive progression after BCG therapy and died as a result of tumor progression, while in the non-BCG group (n=15), 8 cases (53.3%) developed recurrence, only one case had progression and died of cancer. In the CIS-BCG group (n=5), 3 patients (60.0%) had recurrent tumor and 2 had invasive progression. Univariate analysis (Logrank test) demonstrated that tumor size and adjuvant instillation of BCG were associated with tumor recurrence except for carcinoma in situ, but tumor progression and survival did not differ significantly. Our results suggest that BCG therapy prevents grade 3 superficial bladder cancer (pT1, pTa) recurrence.
